- Conditions
- Vital Sign Monitoring
- Interventions
- Investigational Group, Reference group
- Device
- Lead sponsor
- Darma Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 440
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Plaque Psoriasis
- Interventions
- roflumilast cream 0.3%, Zoryve, Placebo
- Drug
- Lead sponsor
- Padagis LLC
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Sleep Deprivation, Nutritional Intervention
- Interventions
- Ketogenic Intervention, Mediterranean Intervention, Placebo, Ketone Ester
- Other · Dietary Supplement
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Persistent Post Concussion Syndrome, Mild Traumatic Brain Injury
- Interventions
- Active tDCS, Sham tDCS
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Breast Cancer, Cancer of the Breast
- Interventions
- VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Healthy
- Interventions
- Not listed
- Lead sponsor
- Mead Johnson Nutrition
- Industry
- Eligibility
- 10 Days to 18 Days
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Lake Mary, Florida + 7 more
- Conditions
- Heart Failure
- Interventions
- ACE inhibitor, Sacubitril/Valsartan
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,066 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Participants
- Interventions
- Evolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference)
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 405 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 4
- States / cities
- Anaheim, California • South Miami, Florida • Springfield, Missouri + 1 more
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Interventions
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 781,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 13
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more
- Conditions
- Acne Vulgaris
- Interventions
- Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel, Placebo
- Drug
- Lead sponsor
- Zydus Lifesciences Limited
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 12
- States / cities
- Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more
- Conditions
- Multi-drug Resistant Tuberculosis
- Interventions
- Pretomanid
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Tobacco Smoking, Tobacco Use
- Interventions
- Not listed
- Lead sponsor
- Altria Client Services LLC
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Stockbridge, Georgia
- Conditions
- Non-small Cell Lung Cancer, Metastatic Lung Cancer
- Interventions
- Pembrolizumab + Pemetrexed-Platinum, Pemetrexed-Platinum
- Drug
- Lead sponsor
- Aetion, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 1,854 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Speech Sound Disorder
- Interventions
- Visual acoustic biofeedback: ORDER, Perception Training: ORDER
- Behavioral
- Lead sponsor
- Montclair State University
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Montclair, New Jersey
- Conditions
- Cardiac Output, Low
- Interventions
- non-invasive cardiac output monitor
- Device
- Lead sponsor
- CareTaker Medical LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Camden, New Jersey
- Conditions
- Prostate Cancer
- Interventions
- Degarelix, Leuprolide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- Male only
- Enrollment
- 14,417 participants
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sarcopenia
- Interventions
- DXA scanning
- Radiation
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
- Drug
- Lead sponsor
- Amneal Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more
- Conditions
- Major Depressive Disorder
- Interventions
- desvenlafaxine succinate sustained release, fluoxetine, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 41
- States / cities
- Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
- Conditions
- Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
- Interventions
- Method(s)1 Attribution, Method(s)2 Attribution,
- Drug
- Lead sponsor
- DR. DIANE CHISESI NFS. MD. PHD.
- Other
- Eligibility
- 44 Years to 59 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Colorado Springs, Colorado
- Conditions
- Sepsis, Septic Shock, Healthy
- Interventions
- Blood collection
- Device
- Lead sponsor
- Abionic SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Fentanyl, Opioid Use, Surgery, Respiratory Complication
- Interventions
- Fentanyl dose administration
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 183,396 participants
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Subjects
- Interventions
- Quizartinib, Rufinamide
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas